A critical review of fosphenytoin sodium injection for the treatment of status epilepticus in adults and children

References

• Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus–Report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015 Oct;56(10):1515–1523. Epub 2015 Sep 4. PMID: 26336950.
   PubMed Web of Science ®Google Scholar
• Shinnar S, Berg AT, Moshe SL, et al. How long do new-onset seizures in children last? Ann Neurol. 2001 May;49(5):659–664. PMID: 11357957.
   PubMed Web of Science ®Google Scholar
• Dobesberger J, Ristić AJ, Walser G, et al. Duration of focal complex, secondarily generalized tonic-clonic, and primarily generalized tonic-clonic seizures–A video-EEG analysis. Epilepsy Behav. 2015 Aug;49:111–117. Epub 2015 Apr 29. PMID: 25935513.
   PubMed Web of Science ®Google Scholar
• Meldrum BS. Metabolic factors during prolonged seizures and their relation to nerve cell death. Adv Neurol. 1983;34:261–275. PMID: 6829335.
   PubMedGoogle Scholar
• Hesdorffer DC, Logroscino G, Cascino G, et al. Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology. 1998 Mar;50(3):735–741. PMID: 9521266.
   PubMed Web of Science ®Google Scholar
• DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996 Apr;46(4):1029–1035. PMID: 8780085.
   PubMed Web of Science ®Google Scholar
• Govoni V, Fallica E, Monetti VC, et al. Incidence of status epilepticus in Southern Europe: a population study in the health district of Ferrara, Italy. Eur Neurol. 2008;59(3–4):120–126. Epub 2007 Nov 30. PMID: 18057897.
   PubMed Web of Science ®Google Scholar
• Leitinger M, Trinka E, Giovannini G, et al. Epidemiology of status epilepticus in adults: a population-based study on incidence, causes, and outcomes. Epilepsia. 2019 Jan;60(1):53–62. Epub 2018 Nov 26. PMID: 30478910; PMCID: PMC7380005.
   PubMed Web of Science ®Google Scholar
• Scholtes FB, Renier WO, Meinardi H. Generalized convulsive status epilepticus: causes, therapy, and outcome in 346 patients. Epilepsia. 1994 Sep-Oct;35(5):1104–1112. PMID: 7925159.
   PubMed Web of Science ®Google Scholar
• Sutter R, Kaplan PW. The neurophysiologic types of nonconvulsive status epilepticus: EEG patterns of different phenotypes. Epilepsia. 2013 Sep;54(Suppl 6):23–27. PMID: 24001065.
   PubMed Web of Science ®Google Scholar
• Leitinger M, Beniczky S, Rohracher A, et al. Salzburg consensus criteria for non-convulsive status epilepticus–approach to clinical application. Epilepsy Behav. 2015 Aug;49:158–163. Epub 2015 Jun 17. PMID: 26092326.
   PubMed Web of Science ®Google Scholar
• Vignatelli L, Tonon C, D’Alessandro R, et al. Incidence and short-term prognosis of status epilepticus in adults in Bologna, Italy. Epilepsia. 2003 Jul;44(7):964–968. PMID: 12823581.
   PubMed Web of Science ®Google Scholar
• Maytal J, Shinnar S, Moshé SL, et al. Low morbidity and mortality of status epilepticus in children. Pediatrics. 1989 Mar;83(3):323–331. PMID: 2919138.
   PubMed Web of Science ®Google Scholar
• Waterhouse EJ, Vaughan JK, Barnes TY, et al. Synergistic effect of status epilepticus and ischemic brain injury on mortality. Epilepsy Res. 1998 Feb;29(3):175–183. PMID: 9551779.
   PubMed Web of Science ®Google Scholar
• Sánchez Fernández I, Amengual-Gual M, Barcia Aguilar C, et al. Estimating the cost of status epilepticus admissions in the United States of America using ICD-10 codes. Seizure. 2019 Oct;71:295–303. Epub 2019 Sep 4. PMID: 31518880.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Ambrosi M, Pavone P, et al. Pediatric status epilepticus: improved management with new drug therapies? Expert Opin Pharmacother. 2017;18(8):789–798.
   PubMed Web of Science ®Google Scholar
• Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. Epilepsy Curr. 2016 Jan-Feb;16(1):48–61. PMID: 26900382; PMCID: PMC4749120.
   PubMed Web of Science ®Google Scholar
• Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998 Sep 17;339(12):792–798. PMID: 9738086.
   PubMed Web of Science ®Google Scholar
• Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001 Aug 30;345(9):631–637. Erratum in: N Engl J Med 2001 Dec 20;345(25):1860. PMID: 11547716.
   PubMed Web of Science ®Google Scholar
• Silbergleit R, Lowenstein D, Durkalski V, et al. RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. Epilepsia. 2011 Oct;52(Suppl8): 45–47. Neurological Emergency Treatment Trials (NETT) Investigators.
   PubMedGoogle Scholar
• Alldredge BK, Wall DB, Ferriero DM. Effect of prehospital treatment on the outcome of status epilepticus in children. Pediatr Neurol. 1995 Apr;12(3):213–216. PMID: 7619187.
   PubMed Web of Science ®Google Scholar
• McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005 Jul 16-22;366(9481):205–210. PMID: 16023510.
   PubMed Web of Science ®Google Scholar
• Gilad R, Izkovitz N, Dabby R, et al. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand. 2008 Nov;118(5):296–300. PMID: 18798830.
   PubMed Web of Science ®Google Scholar
• Höfler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia. 2013 Mar;54(3):393–404. Epub 2013 Jan 7. PMID: 23293881.
   PubMed Web of Science ®Google Scholar
• Claassen J, Hirsch LJ, Mayer SA. Treatment of status epilepticus: a survey of neurologists. J Neurol Sci. 2003 Jul 15;211(1–2):37–41. PMID: 12767495.
   PubMed Web of Science ®Google Scholar
• Chamberlain JM, Okada P, Holsti M, et al. Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. JAMA. 2014 Apr 23-30;311(16):1652–1660. Pediatric Emergency Care Applied Research Network (PECARN). PMID: 24756515.
   PubMed Web of Science ®Google Scholar
• Boucher BA, Feler CA, Dean JC, et al. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. Pharmacotherapy. 1996 Jul-Aug;16(4):638–645. PMID: 8840370.
   PubMed Web of Science ®Google Scholar
• Leppik IE, Goel V, Rarick J, et al. Intramuscular and intravenous levetiracetam in humans: safety and pharmacokinetics. Epilepsy Res. 2010 Oct;91(2–3):289–292. Epub 2010 Aug 14. PMID: 20708904.
   PubMed Web of Science ®Google Scholar
• Husain AM, Lee JW, Kolls BJ, et al. Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizures. Ann Neurol. 2018 Jun;83(6):1174–1185. PMID: 29733464; PMCID: PMC6785201.
   PubMed Web of Science ®Google Scholar
• Orlandi N, Bartolini E, Audenino D, et al. Intravenous brivaracetam in status epilepticus: a multicentric retrospective study in Italy. Seizure. 2021 Mar;86:70–76. Epub 2021 Jan 30. PMID: 33561784.
   PubMed Web of Science ®Google Scholar
• Claassen J, Hirsch LJ, Emerson RG, et al. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002 Feb;43(2):146–153. PMID: 11903460.
   PubMed Web of Science ®Google Scholar
• Cervenka MC, Hocker S, Koenig M, et al. Phase I/II multicenter ketogenic diet study for adult superrefractory status epilepticus. N eurology. 2017 Mar 7;88(10):938–943. Epub 2017 Feb 8. PMID: 28179470; PMCID: PMC5333514.
   PubMed Web of Science ®Google Scholar
• Merritt HH, Putnam TJ. Landmark article Sept 17, 1938: sodium diphenyl hydantoinate in the treatment of convulsive disorders. By H. Houston Merritt and Tracy J. Putnam. JAMA. 1984 Feb 24;251(8):1062–1067. PMID: 6363736.
   PubMed Web of Science ®Google Scholar
• Mattson RH. Parenteral antiepileptic/anticonvulsant drugs. Neurology. 1996 Jun;46(6 Suppl 1):S8–13. PMID: 8649613.
   PubMed Web of Science ®Google Scholar
• Spengler RF, Arrowsmith JB, Kilarski DJ, et al. Severe soft-tissue injury following intravenous infusion of phenytoin. Patient and drug administration risk factors. Arch Intern Med. 1988 Jun;148(6):1329–1333. PMID: 3377616.
   PubMedGoogle Scholar
• Earnest MP, Marx JA, Drury LR. Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usage. JAMA. 1983 Feb 11;249(6):762–765. PMID: 6823029.
   PubMed Web of Science ®Google Scholar
• Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology. 1996 Jun;46(6 Suppl 1):S3–7. PMID: 8649612.
   PubMed Web of Science ®Google Scholar
• Boucher BA. Fosphenytoin: a novel phenytoin prodrug. Pharmacotherapy. 1996 Sep-Oct;16(5):777–791. PMID: 8888074.
   PubMed Web of Science ®Google Scholar
• Conway JM. Chapter 58 Phenytoin and fosphenytoin. In: Wyllie E, editor. Wyllie’s treatment of epilepsy: principles and practice. 7th ed. Philadelphia (PA): Wolters Kluwer; 2020. p. 678–692.
   Google Scholar
• Pfizer Inc. CEREBYX® - fosphenytoin sodium injection, solution. US prescribing information. 2021 [cited 2021 Apr 14]. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=749
   Google Scholar
• US Food and Drug Administration. Drug databases. Drugs@FDA. Abbreviated New Drug Application (ANDA): 078126. 2021. [cited 2021 Apr 14]. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=749
   Google Scholar
• Sedor Pharmaceuticals LLC. SESQUIENT - fosphenytoin sodium injection, solution. US prescribing information. 2020 [cited 2021 Apr 14]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210864s000lbl.pdf
   Google Scholar
• DeLorenzo R, Sun D. Phenytoin and other hydantoins: mechanism of action. In: Levy R, Mattson R, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA):Lippincott Williams & Wilkins; 2002. p.565–580.
   Google Scholar
• Wang X, Patsalos PN. A comparison of central brain (cerebrospinal and extracellular fluids) and peripheral blood kinetics of phenytoin after intravenous phenytoin and fosphenytoin. Seizure. 2003 Sep;12(6):330–336. PMID: 12915078.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Usui N, Hiroki T, et al. Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers. Eur J Drug Metab Pharmacokinet. 2013 Jun;38(2):139–148. Epub 2012 Sep 12. PMID: 22968854; PMCID: PMC3664181.
   PubMed Web of Science ®Google Scholar
• Leppik IE, Boucher BA, Wilder BJ, et al. Pharmacokinetics and safety of a phenytoin prodrug given i.v. or i.m. in patients. Neurology. 1990 Mar;40(3 Pt 1):456–460. PMID: 2314588.
   PubMed Web of Science ®Google Scholar
• Runge JW, Sloan WP, Turnbull, et al. Intravenous fosphenytoin loading for emergent seizure control. Ann Emerg Med. 1995;25:139.
   Google Scholar
• Pellock JM. Fosphenytoin use in children. Neurology. 1996 Jun;46(6 Suppl 1):S14–6. PMID: 8649608.
   PubMed Web of Science ®Google Scholar
• Garbovsky LA, Drumheller BC, Perrone J. Purple glove syndrome after phenytoin or fosphenytoin administration: review of reported cases and recommendations for prevention. J Med Toxicol. 2015 Dec;11(4):445–459. PMID: 26135797; PMCID: PMC4675605.
   PubMed Web of Science ®Google Scholar
• Jamerson BD, Dukes GE, Brouwer KL, et al. Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacotherapy. 1994 Jan-Feb;14(1):47–52. PMID: 8159601.
   PubMed Web of Science ®Google Scholar
• Kapur J, Elm J, Chamberlain JM, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381(22):2103–2113. PMID: 31774955; PMCID: PMC7098487.
   PubMed Web of Science ®Google Scholar
• Chamberlain JM, Kapur J, Shinnar S, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020;395(10231):1217–1224. Epub 2020 Mar 20. PMID: 32203691; PMCID: PMC7241415.
   PubMed Web of Science ®Google Scholar
• Andrews CO, Turnbull MD, Paloucek FP, et al. Safety and pharmacokinetics of fosphenytoin following intravenous loading dose administration [abstr]. Pharmacotherapy. 1994;14:367.
   Google Scholar
• Fischer JH, Patel TV, Fischer PA. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet. 2003;42(1):33–58. PMID: 12489978.
   PubMed Web of Science ®Google Scholar
• Hussey EK, Dukes GE, Messenheimer JA, et al. Evaluation of the pharmacokinetic interaction between diazepam and ACC-9653 (a phenytoin prodrug) in healthy male volunteers [abstract]. Pharm Res. 1990 Nov;7(11):1172–1176. PMID: 2293218.
   PubMed Web of Science ®Google Scholar
• Lai CM, Moore P, Quon CY. Binding of fosphenytoin, phosphate ester pro drug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin [abstract]. Res Commun Mol Pathol Pharmacol. 1995 Apr;88(1):51–62. PMID: 7620838.
   PubMed Web of Science ®Google Scholar
• Jamerson BD, Donn KH, Dukes GE, et al. Absolute bioavailability of phenytoin after 3-phosphoryloxymethyl phenytoin disodium (ACC-9653) administration to humans. Epilepsia. 1990 Sep-Oct;31(5):592–597. PMID: 2401249.
   PubMed Web of Science ®Google Scholar
• Gerber N, Mays DC, Donn KH, et al. Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. J Clin Pharmacol. 1988 Nov;28(11):1023–1032. PMID: 3243914.
   PubMed Web of Science ®Google Scholar
• Morton LD, Pellock JM, Maria BL, et al. Fosphenytoin safety and pharmacokinetics in children [abstract]. Epilepsia. 1997;38(Suppl. 8):194.
   Google Scholar
• Aweeka FT, Gottwald MD, Gambertoglio JG, et al. Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia. 1999 Jun;40(6):777–782. PMID: 10368078.
   PubMed Web of Science ®Google Scholar
• Eldon MA, Loewen GR, Voightman RE, et al. Safety, tolerance, and pharmacokinetics of intravenous fosphenytoin [abstract]. Clin Pharmacol Ther. 1993;53:212.
   Web of Science ®Google Scholar
• Pryor FM, Gidal B, Ramsay RE, et al. Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses. Epilepsia. 2001 Feb;42(2):245–250. PMID: 11240597.
   PubMed Web of Science ®Google Scholar
• Eldon MA, Loewen GR, Voightman RE, et al. Pharmacokinetics and tolerance of fosphenytoin and phenytoin administered intravenously to healthy subjects [abstr]. Can J Neurol Sci. 1993;20(suppl 4):SI80.
   Google Scholar
• Ramsay RE, Philbrook B, Fischer JH, et al. Safety and pharmacokinetics of fosphenytoin (Cerebyx) compared with Dilantin following rapid intravenous administration [abstr]. Neurology. 1996;46(suppl):A245.
   Google Scholar
• Fischer J, Turnbull T, Uthman B, et al. Safety, tolerance, and pharmacokinetics of intravenous loading doses of fosphenytoin (Cerebyx) versus (Dilantin) [abstr]. Neurology. 1995;45(suppl 4):A202–3.
   Web of Science ®Google Scholar
• Wilder BJ, Ramsay E, Marriott J, et al. Safety and tolerance of intramuscular administration of fosphenytoin, a phenytoin prodrug, for 5 days in patients with epilepsy [abstr]. Neurology. 1993;43(suppl2):A308.
   Google Scholar
• Ramsay E, Barkley GL, Garnett WR, et al. Safety and tolerance of intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin [abstr]. Neurology. 1995;45(suppl 4):A249.
   Web of Science ®Google Scholar
• Allen FH, Runge JW, Legarda S, et al. Safety, tolerance, and pharmacokinetics of intravenous fosphenytoin (Cerebyx) in status epilepticus [abstr]. Epilepsia. 1995;36(supp14):90.
   Google Scholar
• Ogutu BR, Newton CR, Muchohi SN, et al. Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. Br J Clin Pharmacol. 2003 Jul;56(1):112–119. Erratum in: Br J Clin Pharmacol. 2003 Oct;56(4):464.PMID: 12848783; PMCID: PMC1884335.
   PubMed Web of Science ®Google Scholar
• Handral A, Veerappa BG, Gowda VK, et al. Levetiracetam versus fosphenytoin in pediatric convulsive status epilepticus: a randomized controlled trial. J Pediatr Neurosci. 2020 Jul-Sep;15(3):252–256. Epub 2020 Nov 6. PMID: 33531940; PMCID: PMC7847106.
   PubMed Web of Science ®Google Scholar
• Nalisetty S, Kandasamy S, Sridharan B, et al. Clinical effectiveness of levetiracetam compared to fosphenytoin in the treatment of benzodiazepine refractory convulsive status epilepticus. Indian J Pediatr. 2020Jul;87(7):512–519. Epub 2020 Feb 22. PMID: 32088913.
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. An open-label, safety, tolerance, and pharmacokinetic study of intravenous and intramuscular fosphenytoin (Cerebyx®) in children (Protocol 982-028). [Internet]. [Updated 2011 Nov 21; cited 2021 May 17]. Available from: http://art45-paediatric-studies-docs.ema.europa.eu/GROUP%20F/fosphenytoin%20sodium/982-028%20EMA%20Pediatrics%20Web%20Synopsis.pdf
   Google Scholar
• Sheridan PH. Clinical review, pediatric supplement NDA 20550 S003, Cerebyx (intravenous fosphenytoin sodium). Silver Spring (MD): US Food and Drug Administration; [internet] 2017 (FDA publication; Ref ID: 4057517). [Cited 2021 May 17]. Available from: https://www.fda.gov/media/103863/download
   Google Scholar
• Lee R, Kim IE, McCulley LV, et al. Pediatric postmarketing pharmacovigilance, cerebyx (Fosphenytoin Sodium). Silver Spring (MD): US Food and Drug Administration; [internet] (FDA publication; Ref ID: 4453265). 2019 [Cited 2021 May 17]. Available from: https://www.fda.gov/media/130822/download
   Google Scholar
• Electronic medicine compendium [Internet]. Surrey (UK): Datapharm Ltd.; [Updated 2020 03; Cited 2021 May 8]. Available from: https://www.medicines.org.uk/emc/product/2260/smpc
   Google Scholar
• European Medicines Agency. List of nationally authorised medicinal products, active substance: fosphenytoin. [Internet]. Amsterdam (ND): Human Medicines Evaluation Division; [Updated 2021 Mar 25; Cited 2021 May 18]. Available from: https://www.ema.europa.eu/en/documents/psusa/fosphenytoin-list-nationally-authorised-medicinal-products-psusa/00001476/202008_en.pdf
   Google Scholar
• Agarwal P, Kumar N, Chandra R, et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure. 2007 Sep;16(6):527–532. Epub 2007 Jul 9. PMID: 17616473.
   PubMed Web of Science ®Google Scholar
• Marchetti A, Magar R, Fischer J, et al. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments. Clin Ther. 1996 Sep-Oct;18(5):953–966. PMID: 8930434.
   PubMed Web of Science ®Google Scholar
• Armstrong EP, Sauer KA, Downey MJ. Phenytoin and fosphenytoin: a model of cost and clinical outcomes. Pharmacotherapy. 1999 Jul;19(7):844–853. PMID: 10417033.
   PubMed Web of Science ®Google Scholar
• Rudis MI, Touchette DR, Swadron SP, et al. Cost-effectiveness of oral phenytoin, intravenous phenytoin, and intravenous fosphenytoin in the emergency department. Ann Emerg Med. 2004 Mar;43(3):386–397. PMID: 14985668.
   PubMed Web of Science ®Google Scholar
• Coplin WM, Rhoney DH, Rebuck JA, et al. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin. Neurol Res. 2002 Dec;24(8):842–848. PMID: 12500711.
   PubMed Web of Science ®Google Scholar
• Neurological Emergencies Treatment Trials (NETT) Network. Home page. [Internet]. Ann Arbor (MI): University of Michigan; National Institute of Neurological Disorders and Stroke; [Cited 2021 May 19]. Available from: https://nett.umich.edu/
   Google Scholar
• American Epilepsy Society. Clinical guidance. [Internet]. Chicago (IL); [Cited 2021 May 19]. Available from: https://www.aesnet.org/clinical-care/clinical-guidance
   Google Scholar
• Epilepsy Foundation of America. Resource library. [Internet]. Bowie (MD). [Cited 2021 May 19]. Available from: https://www.epilepsy.com/living-epilepsy/epilepsy-and/professional-health-care-providers/resource-library
   Google Scholar